コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 cerebrovascular disease, heart failure, and peripheral vascular disease).
2 ain (ischemic stroke), or lower extremities (peripheral vascular disease).
3 uated as a gene therapy for the treatment of peripheral vascular disease.
4 r cardiovascular endpoints such as stroke or peripheral vascular disease.
5 raphy in patients known or suspected to have peripheral vascular disease.
6 VEGF-induced angiogenesis as well as severe peripheral vascular disease.
7 nsient ischemic attack, and new diagnosis of peripheral vascular disease.
8 One subject also had premature coronary and peripheral vascular disease.
9 and in the treatment of coronary artery and peripheral vascular disease.
10 tion, diabetes, hypertension, and history of peripheral vascular disease.
11 s in women, older patients and patients with peripheral vascular disease.
12 sing prevalence and associated complexity of peripheral vascular disease.
13 aphic follow-up of patients with coronary or peripheral vascular disease.
14 3 mg/dl, and the patient has no worsening of peripheral vascular disease.
15 tive heart failure, renal insufficiency, and peripheral vascular disease.
16 contrast volume and ionicity, and extent of peripheral vascular disease.
17 agement of patients with coronary artery and peripheral vascular disease.
18 luenced graft failure censored for death was peripheral vascular disease.
19 sociated with coronary heart disease but not peripheral vascular disease.
20 ot associated with coronary heart disease or peripheral vascular disease.
21 derwent MR angiography for the evaluation of peripheral vascular disease.
22 ept in conjunction with renal dysfunction or peripheral vascular disease.
23 ial infarction, congestive heart failure, or peripheral vascular disease.
24 ythmias, stroke, venous thromboembolism, and peripheral vascular disease.
25 , cardiac arrest, chronic heart disease, and peripheral vascular disease.
26 s should be considered for all patients with peripheral vascular disease.
27 tor for ischemic heart, cerebrovascular, and peripheral vascular disease.
28 ary calcium, coronary revascularization, and peripheral vascular disease.
29 r severe calcification, and in patients with peripheral vascular disease.
30 s in the OZR, a model of non-atherosclerotic peripheral vascular disease.
31 included a history of diabetes, smoking, and peripheral vascular disease.
32 fested as myocardial infarction, stroke, and peripheral vascular disease.
33 tion distinct from patients with coronary or peripheral vascular disease.
34 esentation of coronary, cerebrovascular, and peripheral vascular diseases.
35 0.0001), diabetes (0.62, 0.43-0.90; p=0.01), peripheral vascular disease (0.27, 0.17-0.45; p<0.0001),
37 69), peptic ulcer disease (1.27; 1.03-1.58), peripheral vascular disease (1.38; 1.07-1.77), renal dis
38 mm Hg), 1.86 for diabetes mellitus, 1.83 for peripheral vascular disease, 1.79 for smoking (>20 cigar
39 17/1,000 years, p < 0.001), and symptomatic peripheral vascular disease (10.6 vs. 3.5/1,000 years, p
40 %, female gender 28%, diabetes mellitus 27%, peripheral vascular disease 11%, cerebrovascular disease
41 etes mellitus (37.1%), hypertension (80.5%), peripheral vascular disease (15.3%), and renal disease (
42 (relative risk 2.79 [95% CI 1.28-6.93]) and peripheral vascular disease (2.83 [1.29-6.17]), but not
43 duced kidney function (31% vs. 24%), and had peripheral vascular disease (21% vs. 11%) more often tha
44 tery bypass graft surgery (19.8% vs. 61.2%), peripheral vascular disease (36.4% vs. 46.9%), diabetes
45 %), infections (12.8%), bleeding (7.6%), and peripheral vascular disease (4.3%) were the most common
47 s strongly predictive of cerebral (5.80) and peripheral vascular disease (5.22), whereas ischemic hea
48 re hypertension (63% vs. 55%, respectively), peripheral vascular disease (8.2% vs. 5.2%, respectively
49 rs and 84 patients with clinically suspected peripheral vascular disease, a stepping kinematic imagin
50 ior stroke, prior transient ischemic attack, peripheral vascular disease, absence of prior coronary a
52 -duration sleeper were higher among men with peripheral vascular disease (adjusted odds ratio (aOR) =
53 nsion, diabetes, ischaemic heart disease and peripheral vascular disease (adjusted OR=1.4, 2.0, 1.9 a
54 rs for ischemic heart disease, cerebral, and peripheral vascular disease after 706 renal transplants,
55 ngiography for evaluation of lower extremity peripheral vascular disease after conventional digital s
56 Heart Failure Model, the PACE (incorporating peripheral vascular disease, age, creatinine, and ejecti
57 more between arms have been associated with peripheral vascular disease and attributed to subclavian
58 its of LDL cholesterol reduction extend into peripheral vascular disease and cerebrovascular disease
59 men and white and with a lower prevalence of peripheral vascular disease and history of prior cardiac
61 ee categories: no diabetes, diabetes without peripheral vascular disease and renal failure, and diabe
63 c syndrome is an independent risk factor for peripheral vascular disease and thrombotic events within
66 esterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoimmune diseases.
67 logistic regression, CAC, ECG R-R variation, peripheral vascular disease, and Beck Depression Invento
68 disease, cerebral infarction, heart failure, peripheral vascular disease, and cardiac arrhythmia) and
69 ropathy, retinopathy, peripheral neuropathy, peripheral vascular disease, and cardiovascular disease.
70 were coronary artery disease, graft failure, peripheral vascular disease, and cause of end-stage rena
71 gher prevalence of coronary atherosclerosis, peripheral vascular disease, and cerebrovascular calcifi
72 isk of myocardial infarction, heart failure, peripheral vascular disease, and cerebrovascular disease
73 ASCVD was defined as coronary heart disease, peripheral vascular disease, and cerebrovascular disease
74 e indication, bipolar depression, age group, peripheral vascular disease, and cognitive performance.
75 on and other coronary heart disease, stroke, peripheral vascular disease, and congestive heart failur
76 (heart attack and angina pectoris), stroke, peripheral vascular disease, and diabetes, 81.7% (140 mi
77 it (such as coronary heart disease, stroke, peripheral vascular disease, and heart failure) over a f
79 splantation comorbidities (diabetes, angina, peripheral vascular disease, and MI), transplantation fr
81 Heart failure, renal failure, liver disease, peripheral vascular disease, and non-atrial fibrillation
82 infarction, cerebrovascular disease, sepsis, peripheral vascular disease, and organ transplantation.
84 k factor for stroke, ischemic heart disease, peripheral vascular disease, and progressive renal damag
86 portal hypertension, ischemic heart disease, peripheral vascular disease, and tumor angiogenesis.
87 ervention, prior myocardial infarction (MI), peripheral vascular disease, and ulcerated lesion (P<0.0
88 ug-coated balloons are increasingly used for peripheral vascular disease, and, yet, mechanisms of tis
89 farction, ischemic heart disease, stroke, or peripheral vascular disease; and had greater baseline se
90 er income; dementia; chronic kidney disease; peripheral vascular disease; and, among patients aged 65
91 e, hypertension, chronic kidney disease, and peripheral vascular disease; and, among those aged 66 ye
92 .44 in network 17 versus 1.00 in network 1), peripheral vascular disease (AOR, 1.65), black race (AOR
93 enges, which include acute aortic syndromes, peripheral vascular disease, aortic stent-graft and tran
94 Patients who require surgical treatment of peripheral vascular disease are at increased risk of per
95 athogenesis of cerebrovascular, coronary and peripheral vascular disease as well as corneal opacifica
96 troke, carotid disease, aortic aneurysm, and peripheral vascular disease), as well as those individua
97 ath from any cause, but a risk reduction for peripheral vascular disease associated with tight blood-
98 he rate of cognitive decline associated with peripheral vascular disease, atherosclerosis of the comm
99 gistic regression analysis identified shock, peripheral vascular disease, balloon angioplasty strateg
100 egaly any time before discharge, presence of peripheral vascular disease, body mass index <20 kg/m2,
101 factors are very prevalent in patients with peripheral vascular disease, but these patients receive
103 tive heart failure, cerebrovascular disease, peripheral vascular disease, cardiac arrhythmias and the
104 enal failure (serum creatinine = 2.5 mg/dL), peripheral vascular disease, cerebrovascular accident, a
105 een arms, with data for subclavian stenosis, peripheral vascular disease, cerebrovascular disease, ca
106 ellitus, as well as comorbidities, including peripheral vascular disease, cerebrovascular disease, ch
107 ties (coronary heart disease, heart failure, peripheral vascular disease, chronic lung disease, diabe
108 nge in the prevalence of cerebrovascular and peripheral vascular disease, chronic obstructive pulmona
109 r dysfunction, increasing age, cardiomegaly, peripheral vascular disease, chronic renal insufficiency
111 ut for angina, congestive heart failure, and peripheral vascular disease, concordance was only fair t
112 eral comorbidities (cerebrovascular disease, peripheral vascular disease, congestive heart failure, c
113 increased serum creatinine, presence of RAS, peripheral vascular disease, congestive heart failure, d
114 ovascular disease, cerebrovascular accident, peripheral vascular disease, diabetes mellitus, liver di
115 nary bypass, acute cerebrovascular ischemia, peripheral vascular disease, diabetes mellitus, preeclam
116 2,000, prior CABG, congestive heart failure, peripheral vascular disease, diabetes, hypertension, and
117 diabetes, dyslipidemia, smoking, cerebral or peripheral vascular disease, etc.) contributing to incre
118 The incidence of cerebrovascular events and peripheral vascular disease events is similar in patient
120 ce of 10 mm Hg or higher was associated with peripheral vascular disease (five studies; RR 2.4, 1.5-3
121 below knee amputation from 14 patients with peripheral vascular disease following quantification of
122 iminate the excess of cardiac, cerebral, and peripheral vascular diseases found in diabetic patients.
123 , chronic obstructive pulmonary disease, and peripheral vascular disease had greater prognostic signi
124 The development of cell therapies to treat peripheral vascular disease has proven difficult because
125 without the sequelae of renal failure and/or peripheral vascular disease have long-term survival simi
126 rial fibrillation (2.84; 95% CI, 1.46-5.53), peripheral vascular disease (hazard ratio, 2.02; 95% CI,
127 Diabetes was associated with hypertension, peripheral vascular disease, history of stroke, clinical
128 (HR 1.41), myocardial infarction (HR 1.34), peripheral vascular disease (HR 1.27), and revasculariza
129 8; 95% confidence interval [CI], 1.39-1.80), peripheral vascular disease (HR=1.41; 95% CI, 1.11-1.80)
130 cer hospitalizations, insulin treatment, and peripheral vascular disease; HR=1.19, 95% CI=1.04-1.36,
131 (deep venous thrombosis/pulmonary embolism, peripheral vascular disease, hypercoagulable state, myoc
134 eatment strategy for patients with extensive peripheral vascular disease in whom the use of intravasc
135 ncidence of 12 cardiac, cerebrovascular, and peripheral vascular diseases in women and men at differe
136 c events (myocardial infarction, stroke, and peripheral vascular disease) in a prospective cohort of
140 ischemic conditions such as severe end-stage peripheral vascular disease, ischemic heart disease and
141 a major risk factor for coronary artery and peripheral vascular diseases, its role in the pathogenes
142 ge, diabetes mellitus, chronic lung disease, peripheral vascular disease, left main trunk stenosis, a
143 , diabetes mellitus, stroke, upper leg pain, peripheral vascular disease, left ventricular hypertroph
144 renal insufficiency, low ejection fraction, peripheral vascular disease, lesion characteristics, fem
145 cardiogenic shock, renal disease, history of peripheral vascular disease, multivessel disease, widowh
146 ischemic heart disease, cerebrovascular, and peripheral vascular disease), musculoskeletal disorders,
147 ypertension; intermediate (0.40 to 0.52) for peripheral vascular disease, neoplasm, myocardial infarc
148 farction, aortic stenosis, female sex, race, peripheral vascular disease, New York Heart Association
149 ence of 15 mm Hg or more was associated with peripheral vascular disease (nine cohorts; RR 2.5, 95% C
150 lly to image hypoxic tissue in solid tumors, peripheral vascular disease of diabetic origin, blunt br
151 idence of CVD (coronary, cerebrovascular, or peripheral vascular disease or heart failure) during 10
152 lmonary bypass time >120 minutes (OR = 6.2), peripheral vascular disease (OR = 2.2), renal (OR = 3.2)
153 1-2 units, OR, 1.47 [0.98-2.22]) followed by peripheral vascular disease (OR, 1.48 [1.05-2.10]), hist
154 P = .0073), no history of cerebrovascular or peripheral vascular disease (OR, 3.13; P = .0071), recei
155 ed ileus were male sex (OR: 1.7, P < 0.001), peripheral vascular disease (OR: 1.8, P < 0.001), respir
156 1.20; 95% CL: 1.08 to 1.34), and underlying peripheral vascular disease (OR: 4.86; 95% CL: 1.66 to 1
157 5% confidence interval [95% CI] 1.13, 2.82), peripheral vascular diseases (OR 2.21, 95% CI 1.37, 3.60
158 te for diabetic subjects with renal failure, peripheral vascular disease, or both was 9.4 deaths per
159 sk for myocardial infarction, heart failure, peripheral vascular disease, or cerebrovascular disease
160 e likely to be female; to have hypertension, peripheral vascular disease, or cerebrovascular disease;
161 reduced left ventricular ejection fraction, peripheral vascular disease, or chronic obstructive pulm
162 allele in combination with atherosclerosis, peripheral vascular disease, or diabetes mellitus were a
163 any coronary event, a cerebrovascular event, peripheral vascular disease, or heart failure), death, m
166 rted range for CRP as a risk factor for CVD, peripheral vascular diseases, or stroke is 1.34 mg/l to
168 us as the primary cause of ESRD (P = 0.002), peripheral vascular disease (P = 0.004), white race (P =
169 A larger proportion of males suffered from peripheral vascular disease (P = 0.02) and ischemic hear
172 vidence of chronic disease, including severe peripheral vascular disease, patchy cardiac fibrosis, an
173 hildhood body mass index and higher rates of peripheral vascular disease (per each 1-standard deviati
175 Bleeding event, peak troponin T level, and peripheral vascular disease predict mortality within 30
176 me were pretransplant smoking, pretransplant peripheral vascular disease, pretransplant dialysis for
177 od pressure, history of diabetes mellitus or peripheral vascular disease, primary renal disease class
178 a; previous coronary artery bypass grafting; peripheral vascular disease; procedure- and lesion-relat
179 to 3.24, p = 0.02) for in-hospital MACE, and peripheral vascular disease (PVD) (OR: 2.18, CI: 1.34 to
180 oncern for medical practitioners in treating Peripheral Vascular Disease (PVD) and Coronary Artery Di
182 ze renal allograft outcomes in patients with peripheral vascular disease (PVD) at the time of transpl
183 profound increase in risk for development of peripheral vascular disease (PVD) in afflicted persons.
187 line demographics and comorbidities, such as peripheral vascular disease (PVD), diabetes, ischemic he
189 dous advances have occurred in therapies for peripheral vascular disease (PVD); until recently, howev
191 vascular disease, neurodegenerative disease, peripheral vascular disease, renal disease, and several
193 coronary artery disease, cerebral ischemia, peripheral vascular disease, restenosis, and tissue edem
194 iac) was the chief cause of mortality, while peripheral vascular disease resulted in several amputati
195 ial infarction, renal insufficiency/failure, peripheral vascular disease, retinopathy, dementia, and
196 nary syndrome, new-onset angina, symptomatic peripheral vascular disease, stroke, and transient ische
197 opathy, neuropathy, cardiovascular diseases, peripheral vascular diseases, stroke, and periodontal pa
198 the recommended Doppler-aided assessment for peripheral vascular disease than patients living in the
199 heart failure, azotemia, bypass surgery, and peripheral vascular disease than patients with ST-elevat
200 greater risk of skin and bladder cancers and peripheral vascular disease, these results suggest that
201 hours, shock, congestive heart failure, and peripheral vascular disease), to predict in-hospital mor
202 al infarction, cardiac failure, diabetes and peripheral vascular disease, transient ischaemic attack
203 women aged 56-79 years) suspected of having peripheral vascular disease underwent multistation whole
204 +/- 14), who were referred for evaluation of peripheral vascular disease, underwent peripheral contra
205 teries using ultrasonography; measurement of peripheral vascular disease using ankle and brachial blo
206 edures and deaths in the 2 treatment groups; peripheral vascular disease was a predefined secondary o
207 ential clinical utility of this approach for peripheral vascular disease, we investigated the ability
208 meter, moderate or severe calcification, and peripheral vascular disease were associated with higher
209 MR angiographic results in two patients with peripheral vascular disease were compared with their res
211 he case of a diabetic patient with extensive peripheral vascular disease who, after 7 years on hemodi
212 w in patients with severe ischemic heart and peripheral vascular disease, who are not candidates for
213 ction, congestive heart failure, stroke, and peripheral vascular disease with adjusted risk ratios of
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。